1
|
de Maat MF, van de Velde CJ, van der Werff MP, Putter H, Umetani N, Klein-Kranenbarg EM, Turner RR, van Krieken JHJ, Bilchik A, Tollenaar RA, Hoon DS. Quantitative Analysis of Methylation of Genomic Loci in Early-Stage Rectal Cancer Predicts Distant Recurrence. J Clin Oncol 2008; 26:2327-35. [DOI: 10.1200/jco.2007.14.0723] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Purpose There are no accurate prognostic biomarkers specific for rectal cancer. Epigenetic aberrations, in the form of DNA methylation, accumulate early during rectal tumor formation. In a preliminary study, we investigated absolute quantitative methylation changes associated with tumor progression of rectal tissue at multiple genomic methylated-in-tumor (MINT) loci sequences. We then explored in a different clinical patient group whether these epigenetic changes could be correlated with clinical outcome. Patients and Methods Absolute quantitative assessment of methylated alleles was used to assay methylation changes at MINT 1, 2, 3, 12, 17, 25, and 31 in sets of normal, adenomatous, and malignant tissues from 46 patients with rectal cancer. Methylation levels of these biomarkers were then assessed in operative specimens of 251 patients who underwent total mesorectal excision (TME) without neoadjuvant radiotherapy in a multicenter clinical trial. Results Methylation at MINT 2, 3, and 31 increased 11-fold (P = .005), 15-fold (P < .001), and two-fold (P = .02), respectively, during adenomatous transformation in normal rectal epithelium. Unsupervised grouping analyses of quantitative MINT methylation data of TME trial patients demonstrated two prognostic subclasses. In multivariate analysis of node-negative patients, this subclassification was the only predictor for distant recurrence (hazard ratio [HR], 4.17; 95% CI, 1.72 to 10.10; P = .002), cancer-specific survival (HR, 3.74; 95% CI, 1.4 to 9.43; P = .003), and overall survival (HR, 2.68; 95% CI, 1.41 to 5.11; P = .005). Conclusion Methylation levels of specific MINT loci can be used as prognostic variables in patients with American Joint Committee on Cancer stage I and II rectal cancer. Quantitative epigenetic classification of rectal cancer merits evaluation as a stratification factor for adjuvant treatment in early disease.
Collapse
Affiliation(s)
- Michiel F.G. de Maat
- From the Department of Molecular Oncology, John Wayne Cancer Institute; Department of Surgical Pathology, Saint John's Health Center, Santa Monica, CA; Department of Surgery, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden; and Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
| | - Cornelis J.H. van de Velde
- From the Department of Molecular Oncology, John Wayne Cancer Institute; Department of Surgical Pathology, Saint John's Health Center, Santa Monica, CA; Department of Surgery, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden; and Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
| | - Martijn P.J. van der Werff
- From the Department of Molecular Oncology, John Wayne Cancer Institute; Department of Surgical Pathology, Saint John's Health Center, Santa Monica, CA; Department of Surgery, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden; and Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
| | - Hein Putter
- From the Department of Molecular Oncology, John Wayne Cancer Institute; Department of Surgical Pathology, Saint John's Health Center, Santa Monica, CA; Department of Surgery, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden; and Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
| | - Naoyuki Umetani
- From the Department of Molecular Oncology, John Wayne Cancer Institute; Department of Surgical Pathology, Saint John's Health Center, Santa Monica, CA; Department of Surgery, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden; and Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
| | - Elma Meershoek Klein-Kranenbarg
- From the Department of Molecular Oncology, John Wayne Cancer Institute; Department of Surgical Pathology, Saint John's Health Center, Santa Monica, CA; Department of Surgery, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden; and Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
| | - Roderick R. Turner
- From the Department of Molecular Oncology, John Wayne Cancer Institute; Department of Surgical Pathology, Saint John's Health Center, Santa Monica, CA; Department of Surgery, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden; and Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
| | - J. Han J.M. van Krieken
- From the Department of Molecular Oncology, John Wayne Cancer Institute; Department of Surgical Pathology, Saint John's Health Center, Santa Monica, CA; Department of Surgery, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden; and Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
| | - Anton Bilchik
- From the Department of Molecular Oncology, John Wayne Cancer Institute; Department of Surgical Pathology, Saint John's Health Center, Santa Monica, CA; Department of Surgery, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden; and Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
| | - Rob A.E.M. Tollenaar
- From the Department of Molecular Oncology, John Wayne Cancer Institute; Department of Surgical Pathology, Saint John's Health Center, Santa Monica, CA; Department of Surgery, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden; and Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
| | - Dave S.B. Hoon
- From the Department of Molecular Oncology, John Wayne Cancer Institute; Department of Surgical Pathology, Saint John's Health Center, Santa Monica, CA; Department of Surgery, Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden; and Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
| |
Collapse
|